Kidney disease

Molecular therapy for Diabetic nephropathy (DN):  Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am
Molecular therapy for Diabetic nephropathy (DN):  Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Natural product-derived therapy for Diabetic Kidney disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 23/June/2017, 9.39 am
Natural product-derived therapy for Diabetic Kidney disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 23/June/2017, 9.39 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden shows that “Reducing VEGF-B Signaling Ameliorates…

read more
Start Typing